Aca­d­e­mics and re­searchers raise con­cerns with FDA’s plan for ‘in­te­grat­ed re­views’

More than 50 aca­d­e­mics and re­searchers from Har­vard, Yale, Johns Hop­kins and oth­er uni­ver­si­ties around the world are call­ing on the FDA to not re­place its orig­i­nal re­views of med­ical prod­ucts with an “in­te­grat­ed re­view” be­cause of the valu­able in­for­ma­tion that would be lost.

The re­searchers claimed that such a shift would de­prive them of in­for­ma­tion and da­ta on the clin­i­cal stud­ies and tri­als sub­mit­ted to the FDA, in­for­ma­tion on the post­mar­ket­ing re­quire­ments, and re­view­er con­cerns with an ap­pli­ca­tion that might not be in­clud­ed in a sum­ma­ry doc­u­ment like the in­te­grat­ed re­view, among oth­er im­por­tant de­tails.

“The FDA should not re­place in­di­vid­ual re­views with an in­te­grat­ed re­view. Rather, an ad­di­tion­al doc­u­ment that sum­ma­rizes the in­di­vid­ual re­views can be pub­lished, as FDA has al­ready been do­ing in pub­lish­ing ‘Sum­ma­ry Re­view’ doc­u­ments,” the re­searchers wrote.

Sim­i­lar­ly, non­prof­it Pub­lic Cit­i­zen said it “strong­ly ob­jects” to the FDA’s pro­pos­al, which was first ex­plained in a June Fed­er­al Reg­is­ter no­tice. “This ill-con­ceived pro­pos­al would, at the least, be a ma­jor step back­wards in agency trans­paren­cy with re­spect to the da­ta that the agency re­lies on when ap­prov­ing new drugs or bi­o­log­ics and the agency’s as­sess­ment of these da­ta,” Pub­lic Cit­i­zen said.

Health tech­nol­o­gy com­pa­ny Flat­iron Health al­so not­ed that some of the sec­tions in the orig­i­nal doc­u­ment ap­pear to be miss­ing in the new in­te­grat­ed sum­ma­ry. “We al­so note that the new doc­u­ment is con­sid­er­ably short­er than the orig­i­nal, which sug­gests that some po­ten­tial­ly use­ful con­tent may be lost in the new for­mat. We urge FDA to en­sure that high­ly valu­able in­sight in­to re­view­ers’ think­ing is re­tained in the new in­te­grat­ed re­view for­mat. We are par­tic­u­lar­ly in­ter­est­ed in en­sur­ing that any ‘con­sul­ta­tive’ re­views from ex­perts out­side the core re­view team are in­clud­ed in the in­te­grat­ed sum­ma­ry re­view or oth­er­wise ac­ces­si­ble,” the com­pa­ny said.

In­dus­try group BIO, how­ev­er, said the new in­te­grat­ed tem­plate is an im­prove­ment over what the agency of­fers now, but al­so cau­tioned the FDA “to strict­ly lim­it dele­tions to the in­for­ma­tion re­peat­ed across re­view doc­u­ments rather than in­for­ma­tion that FDA deems to not be im­por­tant to ex­ter­nal en­ti­ties.”

BIO of­fered the ex­am­ple of the FDA re­cent­ly trim­ming the con­tent of pub­licly post­ed ac­tion pack­ages, which led to the elim­i­na­tion of “a sig­nif­i­cant num­ber” of meet­ing min­utes. In­dus­try group PhRMA al­so said it is im­por­tant for the FDA to en­sure that the com­bi­na­tion of the in­te­grat­ed re­view doc­u­ment and its ap­pen­dices “is no less com­pre­hen­sive than the ex­ist­ing doc­u­men­ta­tion that is post­ed on Drugs@FDA.”

BIO added: “These doc­u­ments for non-mile­stone de­vel­op­ment phase meet­ings, mid­cy­cle com­mu­ni­ca­tions, and late-cy­cle meet­ings are im­por­tant for stake­hold­ers’ un­der­stand­ing of the evo­lu­tion of the FDA’s think­ing dur­ing the de­vel­op­ment pro­gram and through­out the Agency’s re­view of an ap­pli­ca­tion. Like­wise, ad­min­is­tra­tive and cor­re­spon­dence doc­u­ments should con­tin­ue to be made avail­able.”

On the top­ic of the FDA con­tin­u­ing to re­lease spon­sors’ clin­i­cal study re­ports (CSRs), which the agency is con­sid­er­ing end­ing, the aca­d­e­mics and re­searchers al­so dis­agreed with BIO on what to do.

The aca­d­e­mics and re­searchers of­fered their sup­port for the FDA to con­tin­ue its ef­forts to re­lease CSRs, even though on­ly one has been re­leased so far. But BIO and PhRMA said that the re­lease of CSRs should not be pur­sued by the agency.

BIO al­so called on the FDA to work with the Eu­ro­pean Med­i­cines Agency and Health Cana­da to bet­ter align its trans­paren­cy ef­forts.

Com­ments


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.
Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve to death?

Everyone in the cancer R&D arena is looking to build new franchises around better drugs and combos. And one busy pocket of that space is centered entirely on creating an IL-2 drug that can be as effective as the original without the toxicity that damned it to the sidelines.

Alkermes $ALKS formally tossed its hat into the ring of contenders at virtual ESMO today, highlighting the first glimpse of efficacy for their candidate, ALKS 4230, as both a monotherapy as well as in combination with Merck’s Keytruda.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla (Photo by Steven Ferdman/Getty Images)

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col 'short­ly'

Yesterday, after sustained public pressure as Moderna released its Phase III Covid-19 trial blueprint, Pfizer released its own full trial design for their vaccine trials. The move was designed to boost transparency and shore up public trust in the vaccines, but it also revealed differences in how the two companies are approaching the much-watched studies while failing to satisfy the demands of the fiercest advocates for transparency.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Stronger to­geth­er? Boehringer and Mi­rati team to put first KRAS-KRAS com­bo in the clin­ic

Researchers are still waiting to see how much any of the vaunted KRAS drugs now in the clinic can, after decades of preclinical research and some early human studies, help patients. But while they do, two of the leading developers will look to see whether a KRAS-KRAS combo might pose a better shot than any KRAS alone.

Boehringer Ingelheim and Mirati have signed a collaboration to combine Mirati’s closely-watched lead KRAS inhibitor, MRTX849, in a clinical trial with the pan-KRAS blocker that Boehringer has quietly developed with high expectations behind their flashier contenders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Re­gen­eron, Sanofi eye an­oth­er first for their PD-1 con­tender Lib­tayo with promis­ing da­ta for on­col­o­gy niche

Regeneron and Sanofi took another step forward in the long march towards a greatly expanded market for their late-bloomer PD-1 checkpoint Libtayo.

The two occasional allies posted an objective response rate of 31% for Libtayo among 84 patients suffering from advanced cases of basal cell carcinoma at virtual ESMO. That spotlights progress for 26 patients, 5 of whom had a complete response. The data also reflect a boost in the number of responses seen from the last cut of the numbers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla, Pfizer CEO (Steven Ferdman/Getty Images)

Pfiz­er ex­ecs con­fi­dent­ly tap their top 10 block­busters-to-be. But what are the chances of sur­viv­ing PhI­II, let alone hit­ting these big peak sales es­ti­mates?

Pfizer’s top executive team doesn’t lack for confidence.

Where many Big Pharmas would be reluctant to put a peak sales figure on their late-stage drugs, Pfizer CEO Albert Bourla has shrugged off the usual diffidence to outline where the pharma giant expects to get $15 billion-plus.

The list, outlined this week during their investor presentations, is topped by 3 drugs in the $3 billion-plus peak sales category. They are:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Christian Itin, Autolus CEO (Autolus)

#ES­MO20: Au­to­lus pro­vides glimpse of next-gen­er­a­tion CAR-T pro­gram, show­ing ear­ly pos­i­tive safe­ty da­ta

CAR-T therapies were hailed as a breakthrough when Novartis received the first FDA approval for Kymriah back in 2017. Though highly effective at treating certain types of blood cancers, CAR-Ts are also associated with severe and potentially deadly side effects, including lethal instances of cytokine release syndrome.

With this in mind, Autolus Therapeutics is looking to take a crack at a safer CAR-T and presented Phase II cohort data for its AUTO3 program at virtual ESMO 2020. The data showed that, among the 35 patients in the cohort being treated for r/r diffuse large B cell lymphoma, there were no instances of Grade 3 or higher CRS. Eight individuals saw Grade 1 inflammation while another four patients reached Grade 2.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Sean Bo­hen's break from bio­phar­ma is over. The ex-As­traZeneca CMO has re­tired his Big Phar­ma jer­sey and is now — hap­pi­ly — run­ning a lit­tle biotech

The last I had heard about Sean Bohen, he had stepped out of his high-profile job as chief medical officer at AstraZeneca at the beginning of 2019 as CEO Pascal Soriot triggered a broad-ranging R&D shakeup. And then, earlier this week, I got a chance to catch up.

It turns out that Bohen decided at the time that he would not just jump into a new job in the booming biopharma business. As an oncologist, he had worked on the big programs at AstraZeneca, and before that he was at Genentech. That was good for a ticket to just about anyplace in the big biopharma world. But he felt it was time to stop and think things through.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Covid-19 roundup: UP­DAT­ED: Amid calls for trans­paren­cy, Mod­er­na re­leas­es full PhI­II pro­to­col; As­traZeneca tri­al halt thought to be 'con­firmed trans­verse myelitis,' per CNN

Prominent scientists, public health experts and industry critics have been calling for more transparency from vaccine makers, including the release of the companies’ Phase III trial protocols. On Thursday, Moderna became the first major developer to do so.

“It is usually not what industry does,” CEO Stéphane Bancel told Endpoints News in an interview in advance of their R&D day today. “But given the need there is for the scientific community and the medical community and the media to understand how the vaccine is being developed, to make sure people are confident in the safety of the process, in the governance with scientific independence in the medical world and the like, we’re dropping tomorrow the full protocol. It is unredacted.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.